{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:46:27Z","timestamp":1784609187248,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Beijing Municipal of Science and Technology Major Project","award":["Z211100002921003"],"award-info":[{"award-number":["Z211100002921003"]}]},{"name":"National Natural Science Foundation Program","award":["82272320"],"award-info":[{"award-number":["82272320"]}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7222092"],"award-info":[{"award-number":["7222092"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-level Health Talent Construction Project"},{"name":"Beijing Youan Hospital Construction of Talent Pool Program","award":["YARCKC2022006"],"award-info":[{"award-number":["YARCKC2022006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Most international treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) for people newly diagnosed with human immunodeficiency virus (HIV)-1 infection, but experiences with rapid ART initiation remain limited in China. We aimed to evaluate the efficacy and safety of efavirenz (400 mg) plus lamivudine and tenofovir disoproxil fumarate (EFV + 3TC + TDF) versus coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC\/FTC\/TAF) in rapid ART initiation among men who have sex with men (MSM) who have been diagnosed with HIV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, open-label, randomized clinical trial enrolled MSM aged \u226518 years to start ART within 14 days of confirmed HIV diagnosis. The participants were randomly assigned in a 1:1 ratio to receive EFV (400 mg) + 3TC + TDF or BIC\/FTC\/TAF. The primary end point was viral suppression (&amp;lt;50\u2005copies\/mL) at 48 weeks per US Food and Drug Administration Snapshot analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between March 2021 and July 2022, 300 participants were enrolled; 154 were assigned to receive EFV + 3TC + TDF (EFV group) and 146 BIC\/FTC\/TAF (BIC group). At week 48, 118 (79.2%) and 140 (95.9%) participants in the EFV and BIC group, respectively, were retained in care with viral suppression, and 24 (16.1%) and 1 (0.7%) participant in the EFV and BIC group (P &amp;lt; .001), respectively, discontinued treatment because of adverse effects, death, or lost to follow-up. The median increase of CD4 count was 181 and 223\u2005cells\/\u03bcL (P = .020), respectively, for the EFV and BIC group, at week 48. The overall incidence of adverse effects was significantly higher for the EFV group (65.8% vs 37.7%, P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>BIC\/FTC\/TAF was more efficacious and safer than EFV (400 mg) + 3TC + TDF for rapid ART initiation among HIV-positive MSM in China.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae012","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T14:51:50Z","timestamp":1705589510000},"page":"169-176","source":"Crossref","is-referenced-by-count":18,"title":["Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV\u2013Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4834-7248","authenticated-orcid":false,"given":"Ran","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Zhai","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Wang","sequence":"additional","affiliation":[{"name":"Shijiazhuang Fifth Hospital , Shijiazhuang , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[{"name":"Tianjin Second People's Hospital , Tianjin , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuisong","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhenjiang Third People's Hospital , Zhenjiang , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingquan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Pulmonary Hospital of Lanzhou , Lanzhou , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Wuxi Fifth People's Hospital , Wuxi , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugang","family":"Wang","sequence":"additional","affiliation":[{"name":"Dalian Public Health Clinical Center , Dalian , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xuzhou Infectious Disease Hospital , Xuzhou , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hua","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Lv","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shao","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cai","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-3027","authenticated-orcid":false,"given":"Lili","family":"Dai","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University , Beijing , People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2024071918120603100_ciae012-B1","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization","year":"2021"},{"key":"2024071918120603100_ciae012-B2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2023"},{"key":"2024071918120603100_ciae012-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2024071918120603100_ciae012-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13410","article-title":"Same-day and rapid initiation of antiretroviral therapy in people living with HIV in Asia. How far have we come?","volume":"23","author":"Hung","year":"2022","journal-title":"HIV Med"},{"key":"2024071918120603100_ciae012-B5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/clinchem\/hvz010","article-title":"Undetectable equals untransmittable: a game changer for HIV prevention","volume":"66","author":"Patel","year":"2020","journal-title":"Clin Chem"},{"key":"2024071918120603100_ciae012-B6","first-page":"1106","article-title":"[Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)]","volume":"60","author":"AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2024071918120603100_ciae012-B7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400\u2005mg efavirenz versus standard 600\u2005mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"ENCORE1 Study Group","year":"2014","journal-title":"Lancet"},{"key":"2024071918120603100_ciae012-B8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"NAMSAL ANRS 12313 Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2024071918120603100_ciae012-B9","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"2024071918120603100_ciae012-B10","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1038\/s41467-023-41051-w","article-title":"Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"key":"2024071918120603100_ciae012-B11","doi-asserted-by":"crossref","first-page":"1033098","DOI":"10.3389\/fimmu.2022.1033098","article-title":"A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-na\u00efve patients with advanced HIV infection in Nanjing, China","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"2024071918120603100_ciae012-B12","first-page":"277","article-title":"Therapy initiation and rapid start with bictegravir\/emtricitabine\/tenofovir alafenamide in PLWH","volume":"31","author":"Antinori","year":"2023","journal-title":"Infez Med"},{"key":"2024071918120603100_ciae012-B13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","article-title":"Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine","volume":"11","author":"Wohl","year":"2018","journal-title":"Patient"},{"key":"2024071918120603100_ciae012-B14"},{"key":"2024071918120603100_ciae012-B15","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"2024071918120603100_ciae012-B16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"AIDS"},{"key":"2024071918120603100_ciae012-B17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024071918120603100_ciae012-B18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.46234\/ccdcw2023.129","article-title":"Changes in HIV-1 subtypes\/sub-subtypes, and transmitted drug resistance among ART-na\u00efve HIV-infected individuals\u2014China, 2004\u20132022","volume":"5","author":"Liu","year":"2023","journal-title":"China CDC Wkly"},{"key":"2024071918120603100_ciae012-B19","author":"Biktarvy [package insert]","year":"2021"},{"key":"2024071918120603100_ciae012-B20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","article-title":"Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review","volume":"55","author":"de Fraga","year":"2020","journal-title":"J Gastroenterol"},{"key":"2024071918120603100_ciae012-B21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.35772\/ghm.2019.01021","article-title":"Tenofovir nephrotoxicity among Asians living with HIV: review of the literature","volume":"1","author":"Nishijima","year":"2019","journal-title":"Glob Health Med"},{"key":"2024071918120603100_ciae012-B22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/22221751.2020.1752609","article-title":"Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2024071918120603100_ciae012-B23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024071918120603100_ciae012-B24","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","article-title":"Is tenofovir disoproxil fumarate associated with weight loss?","volume":"35","author":"Shah","year":"2021","journal-title":"AIDS"},{"key":"2024071918120603100_ciae012-B25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/QAI.0000000000002650","article-title":"Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV","volume":"87","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024071918120603100_ciae012-B26","doi-asserted-by":"crossref","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae012\/56612887\/ciae012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/1\/169\/58599987\/ciae012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/1\/169\/58599987\/ciae012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T18:13:07Z","timestamp":1721412787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/1\/169\/7571310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae012","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,15]]},"published":{"date-parts":[[2024,1,17]]}}}